低剂量纳曲酮治疗皮肤科疾病的临床综述
本文综述低剂量纳曲酮(1-5 mg)在炎症性及自身免疫性皮肤病中的应用。LDN 通过短暂阻断阿片受体、拮抗 TLR4 等发挥抗炎止痒作用,对 Hailey-Hailey 病、Darier 病、瘙痒症、扁平苔藓、银屑病、皮肌炎、化脓性汗腺炎及聚焦身体的重复行为等显示疗效,可改善疾病严重度、体表面积受累及相关症状,但临床反应因初始表现而异,且需更大研究优化剂量与管理。
要点
- LDN 为 1-5 mg 纳曲酮,通过短暂阻断阿片受体及拮抗 TLR4 发挥抗炎止痒作用。
- LDN 对 Hailey-Hailey 病、Darier 病、瘙痒、扁平苔藓、银屑病等显示疗效。
- LDN 副作用少于标准剂量纳曲酮,但需更大研究优化剂量与管理。
核心结论
- LDN 在多种炎症性皮肤病中显示疗效,可改善疾病严重度、体表面积受累及相关症状,但临床反应因初始疾病表现而异。
- LDN 副作用较标准剂量纳曲酮少,但仍需更大规模研究优化剂量与管理。
研究设计与样本
- 本文为临床综述,描述 LDN 在炎症性皮肤病中的更新及实用用途、相关副作用、成本障碍及与标准纳曲酮剂量的比较。
主要发现
- LDN 短暂阻断阿片受体,增加配体与受体表达,偏好 κ 受体而非 μ 受体,并减少炎症介质与瘙痒。
- LDN 拮抗非阿片受体,包括促炎性 toll 样受体 4。
- LDN 在 Hailey-Hailey 病、Darier 病、瘙痒症、扁平苔藓、银屑病、皮肌炎、化脓性汗腺炎及聚焦身体的重复行为中显示疗效。
- 有证据支持 LDN 与其他抗炎药物联合使用。
- LDN 常见由药房配制,可能造成获取障碍。
临床怎么用
- LDN 可用于 Hailey-Hailey 病、Darier 病、瘙痒症、扁平苔藓、银屑病、皮肌炎、化脓性汗腺炎及聚焦身体的重复行为等皮肤科情况。
- LDN 可考虑与其他抗炎药物联合使用。
- 处方 LDN 需注意其常需药房配制,可能存在获取障碍。
局限性
- 临床反应可能因初始疾病表现而异。
- 需更大规模研究以优化剂量与管理。
- LDN 常由药房配制,可能带来获取障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Naltrexone is a long-acting opioid receptor antagonist that may be compounded at lower doses (1-5 mg) to treat inflammatory or autoimmune conditions. Low-dose naltrexone (LDN) transiently blocks the opioid receptor, resulting in increased ligand and receptor expression, favoring κ over μ receptors and decreasing inflammatory mediators and itch. In addition, LDN antagonizes nonopioid receptors, including the pro-inflammatory toll-like receptor 4. Altogether, the anti-inflammatory properties of LDN have supported its use in dermatologic conditions, including Hailey-Hailey disease, Darier disease, pruritus, lichen planus, psoriasis, dermatomyositis, hidradenitis suppurativa, and body-focused repetition behaviors. LDN has demonstrated efficacy in treating these dermatologic conditions with improvement in disease severity, body surface area involvement, and associated symptoms. However, clinical response may vary based on initial disease presentation. There is also evidence supporting LDN in combination with other anti-inflammatory agents. Fewer side effects have been reported with LDN compared to standard naltrexone doses, though larger studies are required to optimize dosage and management. LDN is commonly compounded by a pharmacy, which may pose barriers to access. In this clinical review, we describe updated and practical uses of LDN in inflammatory dermatologic conditions, associated side effects, cost barriers, and comparisons to standard naltrexone doses.
引用
- Zhou MH, Elston DM, Morrison BW, et al. Low-dose naltrexone for treatment of dermatologic conditions: A clinical review. J Am Acad Dermatol. 2025. PMID: 40962192. doi:10.1016/j.jaad.2025.09.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。